# A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

> **NCT02312258** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 706 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ixazomib

## Key facts

- **NCT ID:** NCT02312258
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-09
- **Primary completion:** 2019-08-12
- **Final completion:** 2022-08-26
- **Target enrollment:** 706 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02312258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02312258, "A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02312258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*